Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
2
Neutral
6
Bullish
6
Bearish
13
Neutral
6
Bullish
27
Bearish
11
Neutral
0
Bullish
21
Discovery themes featuring this stock
Jubilant Ingrevia is a global player in Specialty Chemicals, CDMO, Nutrition & Health Solutions serving diverse industries. Its diversified product portfolio includes pyridine derivatives, fine chemicals, pharma, and agro intermediates.
The company is prioritizing expansion, evidenced by new plant constructions aimed at boosting production in agrochemical and specialty chemicals sectors. This will support increased demand and strategic growth expectations.
FTAs signed with major regions are anticipated to increase its competitive footing in the US and EU markets, aligning its strategic ambitions with global trade dynamics.
Despite global pricing pressures, the company maintains strong operational resilience, leveraging volume growth and strategic cost optimization to sustain stable performance.
Jubilant Ingrevia is also focusing on emerging segments like semiconductors and AI-applications, positioning itself strategically in high-growth innovation spaces.
Chemicals & Petrochemicals
Specialty Chemicals
11,556 Cr
High Risk
36.4
44.1
2.7
3.7
845.95
535.30
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
4787.00 | 14,814 Cr | 35.97 | 5.56 | 0.23 | 15.65 | 20.00 | 13.91 | ||
1232.00 | 14,222 Cr | 83.61 | 4.31 | 0.12 | 5.10 | 7.68 | 2.77 | ||
3580.00 | 14,045 Cr | 42.92 | 9.94 | 0.28 | 23.19 | 21.43 | 9.99 | ||
1306.90 | 13,487 Cr | 30.40 | 4.27 | 0.65 | 14.03 | 18.72 | 12.36 | ||
725.00 | 11,556 Cr | 36.35 | 3.70 | 0.34 | 8.89 | 10.37 | 5.63 | ||
1780.15 | 9,105 Cr | 50.56 | 5.94 | 0.56 | 11.74 | 15.60 | 9.50 | ||
721.50 | 7,662 Cr | 33.36 | 4.84 | 0.55 | 14.50 | 19.52 | 12.88 | ||
| Median: 7 Co. | — | 1306.90 | 13,487 Cr | 36.35 | 4.84 | 0.34 | 14.03 | 18.72 | 9.99 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Jubilant Ingrevia Ltd (JUBLINGREA) is currently trading at 725.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jubilant Ingrevia is a global player in Specialty Chemicals, CDMO, Nutrition & Health Solutions serving diverse industries. Its diversified product portfolio includes pyridine derivatives, fine chemicals, pharma, and agro intermediates. The company is prioritizing expansion, evidenced by new plant constructions aimed at boosting production in agrochemical and specialty chemicals sectors. This will support increased demand and strategic growth expectations. FTAs signed with major regions are anticipated to increase its competitive footing in the US and EU markets, aligning its strategic ambitions with global trade dynamics. Despite global pricing pressures, the company maintains strong operational resilience, leveraging volume growth and strategic cost optimization to sustain stable performance. Jubilant Ingrevia is also focusing on emerging segments like semiconductors and AI-applications, positioning itself strategically in high-growth innovation spaces.
Over the past 52 weeks, Jubilant Ingrevia Ltd has traded between a low of ₹535.30 and a high of ₹845.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jubilant Ingrevia Ltd has a market capitalization of approximately 11,555.85. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jubilant Ingrevia Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.35 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 11,555.85 Cr, Jubilant Ingrevia Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jubilant Ingrevia Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jubilant Ingrevia Ltd is 36.35. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Uniresearch estimates Q1 FY27 revenue at ₹1,052 crore, compared with ₹1,038 crore in Q1 FY26, implying 1.4% year-on-year growth.
Management said incremental growth is increasingly coming from Specialty Chemicals, including Fine Chemicals and CDMO, which have delivered EBITDA margins of 24–26% and a reported 12% revenue growth with 26% margins.
Revenue in Q4FY25 was ₹1,051 crore versus ₹1,074 crore in Q4FY24, a year-on-year decline of 2.14%.
The stock fell 6.5% in the past week versus the Sensex’s 3.84% drop, and it is down 21.17% YTD compared with a 7.16% fall in the Sensex.
Financial Results
Jubilant Ingrevia Ltd published copies of unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Results were approved by the Board on July 22, 2026 and published in newspapers on July 24, 2026.
Financial Results
Jubilant Ingrevia Ltd submitted newspaper copies of unaudited standalone and consolidated financial results for quarter ended June 30, 2026. Results were approved by the Board on July 22, 2026 and published July 24, 2026.
Earnings Call/Transcript
Jubilant Ingrevia Ltd uploaded the audio recording of the investors' conference call for unaudited results for quarter ended June 30, 2026, held on July 23, 2026. Link provided on company website.
Earnings Call/Transcript
Jubilant Ingrevia has uploaded the audio recording of the investors conference call for unaudited Q1 (quarter ended June 30, 2026) results held on July 23, 2026 on its website.
Financial Results
Jubilant Ingrevia announced Q1 FY27 results: Revenue ₹1,300cr (+25% YoY), EBITDA ₹209cr (+36% YoY), PAT ₹106cr (+41% YoY). Press release and investor presentation issued; investors conference call scheduled for 2026-07-23.
Investor Presentation
Jubilant Ingrevia released its Q1 FY27 press release and investor presentation showing revenue ₹1,300cr, EBITDA ₹209cr and PAT ₹106cr, and notified an investors conference call scheduled for 2026-07-23.
